Morepen Laboratories Limited has reached a major milestone by securing a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs. 825 crore (US$ 91 million) from a prominent global pharmaceutical company.

Supplies for this mandate will begin in 4–5 months, with execution running through Q1 of the next financial year, pending standard regulatory and operational procedures. This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major.

Sushil Suri, Chairman & Managing Director, said: “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programs.”

He added, “We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses.”

Kushal Suri, President – International Growth (API), added: “This level of customer confidence reflects company’s proven ability to qualify, execute, and deliver under regulated-market expectations. We drove the program end-to-end with technical, regulatory, and commercial scale-up, and delivered a solution built for quality, continuity, and scale. The outcome is clear: Morepen’s credibility is validated, and we are now set to convert this into larger, multi-year global opportunities”.